Clinical Study
Risk Factors for Recurrence of Symptomatic Common Bile Duct Stones after Cholecystectomy
Table 2
Univariate analysis of the risk factors for recurrence of symptomatic CBD stone.
| | | Recurrence group () | Nonrecurrence group () | value |
| | Laboratory data | | | | | AST (IU/L) | 248.2 ± 254.0 | 172.6 ± 236.3 | 0.25 | | ALT (IU/L) | 168.1 ± 176.4 | 186.3 ± 205.3 | 0.74 | | TB (mg/dL) | 2.2 ± 2.1 | 2.7 ± 2.5 | 0.49 | | Amylase (IU/L) | 173.0 ± 444.1 | 170.3 ± 426.4 | 0.98 | | Alk-P (IU/L) | 566.3 ± 304.2 | 583.2 ± 496.8 | 0.90 | | γ-GTP (IU/L) | 252.6 ± 222.6 | 376.3 ± 332.8 | 0.16 | | WBC (×106/uL) | 10157.3 ± 4332.1 | 9372.6 ± 4039.2 | 0.48 | | Operation type, % () | | | | | Open | 53.3 (8) | 31.8 (41) | 0.15 | | Laparoscopic | 46.7 (7) | 68.2 (88) | | ERCP attempt, % () | | | | | 1 | 46.7 (7) | 75.2 (97) | 0.03 | | ≥2 | 53.3 (8) | 24.8 (32) | | CBD stone size (mm) | | | | | <10 | 20.0 (3) | 43.4 (56) | 0.10 | | ≥10 | 80.0 (12) | 56.6 (73) | | CBD stone number, % () | | | | | 1 | 13.3 (2) | 47.3 (61) | 0.01 | | ≥2 | 86.7 (13) | 52.7 (68) | | Diverticulum, % () | | | | | Yes | 60 (9) | 47.3 (61) | 0.42 | | No | 40 (6) | 52.7 (68) | | Diverticular type, % () | | | | | Type 1 + Type 2 | 53.3 (8) | 25.6 (33) | 0.03 | | Type 3 + none | 46.7 (7) | 74.4 (96) | | Intrahepatic stone, % () | | | | | Yes | 20 (3) | 4.7 (6) | 0.05 | | No | 80 (12) | 95.3 (123) | | EST, % () | | | | | Yes | 73.3 (11) | 82.2 (106) | 0.48 | | No | 26.7 (4) | 17.8 (23) | | Lithotripsy, % () | | | | | Yes | 13.3 (2) | 6.2 (8) | 0.28 | | No | 86.7 (13) | 93.8 (121) | | CBD diameter (mm) | 20.1 ± 7.1 | 18.7 ± 12.5 | 0.67 | | Distal CBD angle (°) | 143.3 ± 15.2 | 141.5 ± 13.3 | 0.63 | | Distal CBD length (mm) | 41.5 ± 10.6 | 38.6 ± 13.6 | 0.43 |
|
|
AST: aspartate transaminase; ALT: alanine transaminase; TB: total bilirubin; ALK-P: alkaline phosphatase; γ-GTP: gamma guanosine triphosphate; WBC: white blood cell count; ERCP: endoscopic retrograde cholangiopancreatography; CBD: common bile duct; EST: endoscopic sphincterotomy.
|
